Handelsinvest Investeringsforvaltning Acquires 10,000 Shares of Masimo Co. (NASDAQ:MASI)

Handelsinvest Investeringsforvaltning lifted its holdings in shares of Masimo Co. (NASDAQ:MASI) by 50.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 30,000 shares of the medical equipment provider’s stock after purchasing an additional 10,000 shares during the period. Handelsinvest Investeringsforvaltning owned about 0.06% of Masimo worth $4,464,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in MASI. Invesco Ltd. boosted its position in Masimo by 126.3% during the 2nd quarter. Invesco Ltd. now owns 1,235,508 shares of the medical equipment provider’s stock valued at $183,868,000 after buying an additional 689,534 shares during the period. Nuveen Asset Management LLC purchased a new stake in Masimo during the 2nd quarter valued at $25,921,000. Handelsbanken Fonder AB purchased a new stake in Masimo during the 2nd quarter valued at $19,867,000. Janus Henderson Group PLC boosted its position in Masimo by 17.2% during the 2nd quarter. Janus Henderson Group PLC now owns 691,953 shares of the medical equipment provider’s stock valued at $102,976,000 after buying an additional 101,354 shares during the period. Finally, AQR Capital Management LLC boosted its position in Masimo by 10.0% during the 2nd quarter. AQR Capital Management LLC now owns 917,508 shares of the medical equipment provider’s stock valued at $132,507,000 after buying an additional 83,039 shares during the period. 83.08% of the stock is currently owned by institutional investors.

MASI stock traded down $0.34 during midday trading on Tuesday, reaching $145.09. The stock had a trading volume of 75,194 shares, compared to its average volume of 240,963. The company’s fifty day simple moving average is $149.23 and its 200 day simple moving average is $144.92. The company has a market cap of $7.89 billion, a price-to-earnings ratio of 47.88, a price-to-earnings-growth ratio of 1.96 and a beta of 1.19. Masimo Co. has a 52-week low of $98.23 and a 52-week high of $160.25.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.03. The business had revenue of $229.60 million during the quarter, compared to analysts’ expectations of $222.46 million. Masimo had a return on equity of 17.82% and a net margin of 22.15%. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.73 EPS. On average, analysts predict that Masimo Co. will post 3.15 EPS for the current fiscal year.

In other Masimo news, CEO Joe E. Kiani sold 18,437 shares of the business’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $160.02, for a total value of $2,950,288.74. Following the completion of the sale, the chief executive officer now owns 157,678 shares in the company, valued at $25,231,633.56. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Sanford Fitch sold 6,500 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $149.43, for a total value of $971,295.00. Following the completion of the sale, the director now owns 50,745 shares of the company’s stock, valued at approximately $7,582,825.35. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 84,444 shares of company stock valued at $13,193,970. 11.50% of the stock is owned by company insiders.

MASI has been the subject of several analyst reports. BTIG Research reissued a “hold” rating on shares of Masimo in a research report on Thursday, August 1st. BidaskClub cut shares of Masimo from a “buy” rating to a “hold” rating in a research report on Tuesday, October 15th. ValuEngine cut shares of Masimo from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Stifel Nicolaus increased their price target on shares of Masimo from $165.00 to $170.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Finally, UBS Group increased their price target on shares of Masimo from $172.00 to $180.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Masimo presently has a consensus rating of “Buy” and a consensus price target of $159.25.

Masimo Company Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Recommended Story: Trading Ex-Dividend Strategy

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit